SillaJen Inc (215600) - Total Liabilities

Latest as of September 2025: ₩6.58 Billion KRW ≈ $4.46 Million USD

Based on the latest financial reports, SillaJen Inc (215600) has total liabilities worth ₩6.58 Billion KRW (≈ $4.46 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SillaJen Inc (215600) long-term investment share to see how much of total assets are deployed in long-term investments.

SillaJen Inc - Total Liabilities Trend (2015–2024)

This chart illustrates how SillaJen Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 215600 current and non-current assets.

SillaJen Inc Competitors by Total Liabilities

The table below lists competitors of SillaJen Inc ranked by their total liabilities.

Company Country Total Liabilities
Shenzhen Weiye Decoration Group Co Ltd
SHE:300621
China CN¥13.51 Billion
Pitanium Ltd
NASDAQ:PTNM
USA $19.87 Million
Anhui Provincial Architectural Design and Research Institute Co.Ltd.
SHE:301167
China CN¥369.32 Million
Villeroy & Boch AG
XETRA:VIB3
Germany €1.39 Billion
Deep Value Driller AS
OL:DVD
Norway Nkr166.61 Million
A Plus Asset Advisor Co Ltd
KO:244920
Korea ₩266.75 Billion
Caisse Régionale de Crédit Agricole du Morbihan
PA:CMO
France €11.62 Billion
S H Kelkar and Company Limited
NSE:SHK
India Rs14.75 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down SillaJen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SillaJen Inc (215600) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 18.80 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.06 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.05 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SillaJen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SillaJen Inc (2015–2024)

The table below shows the annual total liabilities of SillaJen Inc from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩17.20 Billion
≈ $11.66 Million
-11.35%
2023-12-31 ₩19.40 Billion
≈ $13.15 Million
-20.83%
2022-12-31 ₩24.51 Billion
≈ $16.61 Million
-8.49%
2021-12-31 ₩26.78 Billion
≈ $18.15 Million
+9.11%
2020-12-31 ₩24.54 Billion
≈ $16.63 Million
-12.67%
2018-12-31 ₩28.11 Billion
≈ $19.05 Million
-14.85%
2017-12-31 ₩33.01 Billion
≈ $22.37 Million
-56.66%
2016-12-31 ₩76.16 Billion
≈ $51.61 Million
+15.23%
2015-12-31 ₩66.09 Billion
≈ $44.79 Million
--

About SillaJen Inc

KQ:215600 Korea Biotechnology
Market Cap
$207.81 Million
₩306.65 Billion KRW
Market Cap Rank
#16491 Global
#606 in Korea
Share Price
₩2220.00
Change (1 day)
+0.91%
52-Week Range
₩1844.00 - ₩4975.00
All Time High
₩121250.15
About

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more